<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40701129</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-095X</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>Xinyue capsule treatment on long-term outcomes in patients with stable coronary artery disease after PCI: A 10-year observational follow-up.</ArticleTitle><Pagination><StartPage>157075</StartPage><MedlinePgn>157075</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2025.157075</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0944-7113(25)00714-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although the randomized controlled trial (RCT) demonstrated that Xinyue capsule effectively reduced cardiovascular events within 1 year in stable coronary artery disease (CAD) patients post-PCI, the long-term benefits remain unclear. Therefore, the long-term effects of Xinyue capsule were investigated with a post-trial observational follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between January 2014 and July 2016, 1054 patients were randomly assigned to an initial strategy of receiving either Xinyue capsule or placebo for 24 weeks together with the conventional treatment. Between July and October 2024, we collected clinical outcome data from original trial participants to evaluate long-term effectiveness. The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction, and urgent revascularization, whereas secondary composite endpoint included stroke, rehospitalization due to acute coronary syndrome, and all-cause mortality. The Kaplan-Meier method estimated cumulative event incidences, while multivariable Cox regression calculated hazard ratios (HRs) and 95 % confidence intervals (CIs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Post-trial follow-up information was available for 887 patients. The median follow-up period was 10 years (interquartile range, 9.4-10.1 years). The primary endpoint occurred in 19.43 % of the Xinyue capsule group compared to 24.24 % in the placebo group (HR: 0.727, 95 % CI: 0.560 - 0.942, p = 0.016). Secondary endpoint occurred in 25.09 % of the Xinyue capsule group and 31.87 % in the placebo group (HR: 0.687, 95 % CI: 0.547 - 0.863, p = 0.0012).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early Xinyue capsule intervention in addition to the conventional treatment was associated with a significant reduction in composite cardiovascular endpoint over the subsequent 10 years in patients with stable CAD post-PCI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier GmbH. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China; State Key Laboratory of Traditional Chinese Medicine Syndrome, Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Jianpeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Zhuye</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Changgeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Ruina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiaoning</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Peili</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China. Electronic address: 191593690@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Dazhuo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China; National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China. Electronic address: shidztcm@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002214">Capsules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-term outcomes</Keyword><Keyword MajorTopicYN="N">Observational follow-up</Keyword><Keyword MajorTopicYN="N">Panax quinquefolium saponins</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Stable coronary artery disease</Keyword><Keyword MajorTopicYN="N">Xinyue capsule</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that there are no conflicts of interest related to the content of this manuscript. There are no financial, personal, or professional relationships with any organizations or entities that could have influenced the research or its outcomes. The authors confirm that the study was conducted with integrity and transparency, without any commercial or financial bias.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40701129</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2025.157075</ArticleId><ArticleId IdType="pii">S0944-7113(25)00714-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>